Both epidermal growth factor receptor (EGFR) and RAS gene mutations contribute to the
development of non-small cell lung cancer (NSCLC). Because RAS is one of the …

Purpose: The epidermal growth factor receptor (EGFR) and its downstream factors KRAS
and BRAF are mutated with different frequencies in non–small cell lung cancer and …

Introduction: Epidermal growth factor receptor (EGFR) signaling pathway plays a crucial role
in the development and progression of lung cancer. We searched for mutations of EGFR …

EGFR and KRAS mutation profile in non-small cell lung cancers (NSCLCs) shows wide
variations due to geographic and ethnic background. We aimed to determine the frequency …

BACKGROUND. In western countries, the Kirsten ras oncogene homolog gene (KRAS)
mutation rate is high in patients with nonsmall cell lung cancer (NSCLC), especially in those …

Genetic and epigenetic alterations are considered to play important roles in lung cancer.
Recent studies showed that EGFR and K-RAS mutations exhibited a mutually exclusive …

The epidermal growth factor receptor (EGFR), and its family members play an important role
in the development and progression of lung cancers. It has been reported that somatic …

Dear Sir, Lung cancer is one of the most common malignant diseases in developed
countries and is classified into nonsmall cell lung cancer (NSCLC) and small cell lung …

Background The epidermal growth factor receptor (EGFR) is involved in the development
and progression of lung cancer. Somatic EGFR mutations are predictors of response to …

Background: Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor
receptor (EGFR) gene in lung cancers are associated with increased sensitivity of these …